Figure 1. CUEDC1 expression in lung cancer tissues. (A) Immunohistochemical score of CUEDC1 expression in NSCLC and normal tissues. The staining intensity was scored with grades 0-3. (B) CUEDC1 expression examined by immunohistochemical analysis in 110 NSCLC patients, contained 30 pairs of NSCLC tumor tissues and their corresponding adjacent normal tissues, ***P < 0.001. (C) CUEDC1 expression in fresh NSCLC tumor tissues (T) and matched normal tissues (N) examined by western blotting, *P < 0.05. (D) Patients were classified in two groups, those with (N1) or without (N0) lymph node metastasis. IHC analysis showed that 31% of patients with lymph node metastasis had high CUEDC1 expression, whereas 82% of patients without lymph node metastasis had high CUEDC1 expression. P values were calculated using the χ2 test. (E) Analysis of the lymph node ratio (the ratio of the number of metastatic lymph nodes to the total number of examined lymph nodes) in NSCLC. P values were calculated using Student’s t-test. (F) The GSEA results showed a correlation between CUEDC1 levels and KEGG BARRIER CANCER RELAPSE TUMOR SAMPLE. (G) Kaplan-Meier survival curves of overall (left) and post progression survival (right) for high and low CUEDC1 expression levels. (H) Kaplan-Meier survival curves of overall survival comparing high and low CUEDC1 expression showed estimates of survival probability of lung cancer patients with lymph node metastasis using the Kaplan-Meier plotter database (219468_s_at).